Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

MicroRNA expression profiles of whole blood in lung adenocarcinoma.

Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A.

PLoS One. 2012;7(9):e46045. doi: 10.1371/journal.pone.0046045. Epub 2012 Sep 28.

2.

Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.

Patnaik SK, Kannisto ED, Mallick R, Vachani A, Yendamuri S.

PLoS One. 2017 Jul 25;12(7):e0181926. doi: 10.1371/journal.pone.0181926. eCollection 2017.

3.

miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.

Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ.

J Thorac Oncol. 2011 Mar;6(3):482-8. doi: 10.1097/JTO.0b013e318208c785.

4.

microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom WN, Pass HI.

J Thorac Oncol. 2013 Sep;8(9):1156-62. doi: 10.1097/JTO.0b013e318299ac32.

5.

Clinical evaluation of microRNA expression profiling in non small cell lung cancer.

Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E.

Lung Cancer. 2013 Sep;81(3):388-96. doi: 10.1016/j.lungcan.2013.05.007. Epub 2013 Jun 10.

PMID:
23756108
6.

Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.

Patnaik SK, Kannisto E, Knudsen S, Yendamuri S.

Cancer Res. 2010 Jan 1;70(1):36-45. doi: 10.1158/0008-5472.CAN-09-3153. Epub 2009 Dec 22.

7.

MicroRNA expression differentiates histology and predicts survival of lung cancer.

Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E.

Clin Cancer Res. 2010 Jan 15;16(2):430-41. doi: 10.1158/1078-0432.CCR-09-1736. Epub 2010 Jan 12.

8.

Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers.

Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F.

Int J Cancer. 2010 Dec 15;127(12):2870-8. doi: 10.1002/ijc.25289.

9.

Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer.

Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y.

Eur J Cancer Prev. 2013 Nov;22(6):540-8. doi: 10.1097/CEJ.0b013e32835f3be9.

PMID:
23462458
10.

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.

Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H.

PLoS One. 2012;7(6):e38248. doi: 10.1371/journal.pone.0038248. Epub 2012 Jun 4.

11.

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.

Pak MG, Lee CH, Lee WJ, Shin DH, Roh MS.

Diagn Pathol. 2015 Jul 12;10:99. doi: 10.1186/s13000-015-0339-4.

12.

Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.

Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, Kang MH, Son SM, Lee YM, Choi SY, Yun SJ, Kim WJ, Lee OJ.

Int J Cancer. 2013 Aug 1;133(3):645-52. doi: 10.1002/ijc.28054. Epub 2013 Feb 25.

13.

MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.

Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S.

Cancer Prev Res (Phila). 2009 Sep;2(9):807-13. doi: 10.1158/1940-6207.CAPR-09-0094. Epub 2009 Sep 1.

14.

Salivary microRNAs as promising biomarkers for detection of esophageal cancer.

Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z.

PLoS One. 2013;8(4):e57502. doi: 10.1371/journal.pone.0057502. Epub 2013 Apr 1.

15.

Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.

Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, Xu S.

Int J Mol Med. 2015 Dec;36(6):1720-6. doi: 10.3892/ijmm.2015.2388. Epub 2015 Oct 22.

PMID:
26497897
16.

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M.

J Clin Oncol. 2009 Apr 20;27(12):2030-7. doi: 10.1200/JCO.2008.19.4134. Epub 2009 Mar 9.

PMID:
19273703
17.

Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues.

Guan P, Yin Z, Li X, Wu W, Zhou B.

J Exp Clin Cancer Res. 2012 Jun 6;31:54. doi: 10.1186/1756-9966-31-54.

18.

MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Patnaik S, Mallick R, Kannisto E, Sharma R, Bshara W, Yendamuri S, Dhillon SS.

J Thorac Oncol. 2015 Mar;10(3):446-53. doi: 10.1097/JTO.0000000000000423.

19.

MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.

Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wøjdemann M, Johansen JS.

Mod Pathol. 2012 Dec;25(12):1609-22. doi: 10.1038/modpathol.2012.122. Epub 2012 Aug 10.

20.

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.

Weber DG, Gawrych K, Casjens S, Brik A, Lehnert M, Taeger D, Pesch B, Kollmeier J, Bauer TT, Johnen G, Brüning T.

Dis Markers. 2017;2017:9280170. doi: 10.1155/2017/9280170. Epub 2017 Feb 21.

Supplemental Content

Support Center